Repeat Revascularization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Marizyme Announces Approval for DuraGraft® in India Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 News provided by Share this article Share this article JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft ® is now registered and licensed for import into India through Marizyme's distribution partn...

11 gennaio 2021 | 11.34 LETTURA: 5 minuti DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use th...

11 gennaio 2021 11:38 Fonte: Adnkronos #salute-e-benessere DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the com...

Registration: https://informaconnect.com/biotech-showcase/registration-options/ During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme's pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company's flagship product, DuraGraft , an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graf...

During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme's pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company's flagship product, DuraGraft ®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and sever...